PETALING JAYA: Leap Market-listed Nova Pharma Solutions Bhd
is focused on sustaining the positive trajectory seen in its financial results, following strong growth with a 57.3% increase in year-to-date revenue compared with the same period last year.
In its latest half-year financial report ended Dec 31, 2025 (1H26), the company said it recorded growth in both revenue and pre-tax profit.
Revenue for 1H26 rose 66.48% compared with the same period last year, driven primarily by higher contributions from local biotechnology and pharmaceutical projects.
“The increase highlights the growth in demand for biotechnology services, underpinned by both existing and newly secured contracts in the local market,” the company said.
Pre-tax profit for 1H26 was flat at RM3.8mil, affected by lower gross margins, higher operating expenses, and finance costs.
